Saka W A, Olamoyegun M A, Ashonibare V J, Ashonibare P J, Oladipo A A, Adegbola C A, Kolawole O R, Adeyeni A E, Akinkunmi O A, Adebayo J, Akhigbe T M, Akhigbe R E
Department of Physiology, Ladoke Akintola University of Technology, Ogbomoso, Oyo State, Nigeria.
Endocrinology, Diabetes, & Metabolism Unit, Department of Medicine, Ladoke Akintola University of Technology (LAUTECH)/LAUTECH Teaching Hospital, Ogbomoso, Oyo State, Nigeria.
Biochem Biophys Res Commun. 2025 Sep 8;778:152386. doi: 10.1016/j.bbrc.2025.152386. Epub 2025 Jul 18.
Diabetes is a growing health challenge with a global socio-economic burden. It is associated with several complications, such as cardiac injury. Diabetes-associated cardiac damage is linked with cardiac acetylcholinesterase (AchE) increase and apoptotic injury. Although metformin is established in diabetes management and donepezil is a known acetylcholinesterase (AchE) antagonist, the cardioprotective effect of combining metformin and donepezil in diabetes has yet to be reported.
Consequently, the current study investigated the cardioprotective role of the metformin/donepezil combination in a Wistar rat model of high-fat diet/streptozotocin-induced diabetes. Moreover, the involvements of cardiac AchE and Bax/Bcl-2/caspase signaling were investigated.
Thirty-six 8-week-old male Wistar rats were acclimatized for a week and then randomly allotted into six equal groups (n = 6 rats per group): control, diabetes (DM), DM + metformin, donepezil, DM + donepezil, and DM + metformin + donepezil groups. Diabetes was induced with a high-fat diet/streptozotocin. In addition, DM + Metformin rats received 100 mg/kg of metformin per os, Donepezil received 10 mg/kg of donepezil per os, DM + Donepezil had 10 mg/kg of donepezil per os, and DM + Metformin + Donepezil had 100 mg/kg of metformin with 10 mg/kg of donepezil per os for six weeks.
Metformin and donepezil independently improved fasting glucose, insulin and insulin resistance, and lipid profile in diabetic rats. Also, metformin and donepezil reduced the damage caused by diabetes to the heart, including high levels of injury markers, tissue damage, and amyloid buildup. In addition, metformin and donepezil attenuated oxidative stress (MDA), antioxidant (GSH, SOD, and catalase) decline, inflammation (CRP, TNF-α, IL-1β, and IL-6), apoptosis (Bax/Bcl-2 and caspase-3), and AchE rise in the cardiac tissue of diabetic rats. The combined use of metformin and donepezil exerted a superior effect compared to either monotherapy.
In conclusion, the metformin and donepezil combination exerts cardioprotective effects in diabetic rats through AchE inhibition and Bax/Bcl-2/caspase-3 modulation.
糖尿病是一个日益严峻的健康挑战,带来了全球性的社会经济负担。它与多种并发症相关,如心脏损伤。糖尿病相关的心脏损害与心脏乙酰胆碱酯酶(AchE)增加和凋亡性损伤有关。尽管二甲双胍已用于糖尿病管理,多奈哌齐是一种已知的乙酰胆碱酯酶(AchE)拮抗剂,但二甲双胍与多奈哌齐联合用于糖尿病的心脏保护作用尚未见报道。
因此,本研究在高脂饮食/链脲佐菌素诱导的糖尿病Wistar大鼠模型中,研究了二甲双胍/多奈哌齐联合用药的心脏保护作用。此外,还研究了心脏AchE和Bax/Bcl-2/半胱天冬酶信号通路的参与情况。
将36只8周龄雄性Wistar大鼠适应环境一周,然后随机分为6个相等的组(每组n = 6只大鼠):对照组、糖尿病组(DM)、DM + 二甲双胍组、多奈哌齐组、DM + 多奈哌齐组和DM + 二甲双胍 + 多奈哌齐组。通过高脂饮食/链脲佐菌素诱导糖尿病。此外,DM + 二甲双胍组大鼠口服100 mg/kg二甲双胍,多奈哌齐组口服10 mg/kg多奈哌齐,DM + 多奈哌齐组口服10 mg/kg多奈哌齐,DM + 二甲双胍 + 多奈哌齐组口服100 mg/kg二甲双胍和10 mg/kg多奈哌齐,持续6周。
二甲双胍和多奈哌齐分别改善了糖尿病大鼠的空腹血糖、胰岛素和胰岛素抵抗以及血脂谱。此外,二甲双胍和多奈哌齐减轻了糖尿病对心脏造成的损害,包括高水平的损伤标志物、组织损伤和淀粉样蛋白堆积。此外,二甲双胍和多奈哌齐减轻了糖尿病大鼠心脏组织中的氧化应激(丙二醛)、抗氧化剂(谷胱甘肽、超氧化物歧化酶和过氧化氢酶)下降、炎症(C反应蛋白、肿瘤坏死因子-α、白细胞介素-1β和白细胞介素-6)、细胞凋亡(Bax/Bcl-2和半胱天冬酶-3)以及AchE升高。与单一疗法相比,二甲双胍和多奈哌齐联合使用具有更好的效果。
总之,二甲双胍和多奈哌齐联合用药通过抑制AchE和调节Bax/Bcl-2/半胱天冬酶-3对糖尿病大鼠发挥心脏保护作用。